JP2023542137A5 - - Google Patents
Info
- Publication number
- JP2023542137A5 JP2023542137A5 JP2023517314A JP2023517314A JP2023542137A5 JP 2023542137 A5 JP2023542137 A5 JP 2023542137A5 JP 2023517314 A JP2023517314 A JP 2023517314A JP 2023517314 A JP2023517314 A JP 2023517314A JP 2023542137 A5 JP2023542137 A5 JP 2023542137A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- area
- vitiligo
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17/023,269 | 2020-09-16 | ||
| US17/023,269 US20210030672A1 (en) | 2019-06-10 | 2020-09-16 | Topical treatment of vitiligo by a jak inhibitor |
| PCT/US2021/071479 WO2022061351A1 (en) | 2020-09-16 | 2021-09-16 | Topical treatment of vitiligo |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023542137A JP2023542137A (ja) | 2023-10-05 |
| JP2023542137A5 true JP2023542137A5 (https=) | 2024-08-30 |
Family
ID=78135236
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517314A Pending JP2023542137A (ja) | 2020-09-16 | 2021-09-16 | 白斑の局所処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20230364095A1 (https=) |
| EP (1) | EP4213800A1 (https=) |
| JP (1) | JP2023542137A (https=) |
| CN (1) | CN116261447A (https=) |
| CA (1) | CA3195357A1 (https=) |
| WO (1) | WO2022061351A1 (https=) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| BR0212760A (pt) | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| DE60213842T2 (de) | 2001-10-30 | 2007-09-06 | Novartis Ag | Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| PE20130216A1 (es) * | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| US9642934B2 (en) * | 2013-08-09 | 2017-05-09 | Gunze Limited | Bone regeneration material kit, paste-like bone regeneration material, bone regeneration material, and bone bonding material |
| JP2016540762A (ja) * | 2013-12-02 | 2016-12-28 | ステルス バイオセラピューティックス コープ | 白斑の治療のための組成物及び方法 |
| SG11201701292XA (en) * | 2014-08-27 | 2017-03-30 | Abbvie Inc | Topical formulation |
| MX2018001831A (es) * | 2015-08-14 | 2018-09-06 | Univ Columbia | Biomarcadores para el tratamiento de alopecia areata. |
| US10894837B2 (en) * | 2016-12-16 | 2021-01-19 | Université De Bordeaux | MMP9 inhibitors and uses thereof in the prevention or treatment of a depigmenting disorder |
| US11957931B2 (en) * | 2017-04-26 | 2024-04-16 | Yale University | Compositions and methods for treating vitiligo |
| US20190060311A1 (en) * | 2017-08-24 | 2019-02-28 | Aclaris Therapeutics, Inc. | Compositions and methods for treatment of vitiligo |
| SG11202005781WA (en) * | 2018-01-09 | 2020-07-29 | Dermavant Sciences GmbH | Cerdulatinib-containing topical skin pharmaceutical compositions and uses thereof |
| US20210030672A1 (en) * | 2019-06-10 | 2021-02-04 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
| JP7532511B2 (ja) * | 2019-06-10 | 2024-08-13 | インサイト・コーポレイション | Ｊａｋ阻害剤による尋常性白斑の局所治療 |
-
2021
- 2021-09-16 WO PCT/US2021/071479 patent/WO2022061351A1/en not_active Ceased
- 2021-09-16 US US18/245,019 patent/US20230364095A1/en active Pending
- 2021-09-16 EP EP21791221.1A patent/EP4213800A1/en not_active Withdrawn
- 2021-09-16 CA CA3195357A patent/CA3195357A1/en active Pending
- 2021-09-16 JP JP2023517314A patent/JP2023542137A/ja active Pending
- 2021-09-16 CN CN202180072662.8A patent/CN116261447A/zh active Pending
-
2023
- 2023-02-28 US US18/176,294 patent/US20230293431A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545568A5 (https=) | ||
| US6524623B1 (en) | Therapeutic compositions and methods of use thereof | |
| EP2533785B1 (en) | Treatment of loss of sense of touch with saxitoxin derivatives | |
| JP7532511B2 (ja) | Ｊａｋ阻害剤による尋常性白斑の局所治療 | |
| EP2481747A1 (en) | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists | |
| JP2024105436A5 (https=) | ||
| Fischer et al. | Efficacy and tolerability of ambroxol hydrochloride lozenges in sore throat | |
| HUE034886T2 (hu) | Gyógyszerek cranialis adagolása | |
| US20120083452A1 (en) | Topical Anesthetic Uses of Szeto-Schiller Peptides | |
| US20210030672A1 (en) | Topical treatment of vitiligo by a jak inhibitor | |
| JP2023542137A5 (https=) | ||
| CA3146811A1 (en) | Methods for alleviating pterygium-associated worry about eye appearance | |
| WO2000021531A1 (en) | Remedies for ocular diseases | |
| HUP0100599A2 (hu) | Lokális anesztetikumok új alkalmazása vaszkuláris fejfájások ellen | |
| KR20190134807A (ko) | 중추 신경계의 퇴행성 질환 및/또는 리소솜 저장병을 예방 및/또는 치료하기 위한 신규한 조성물 | |
| Ezz Eldawla et al. | Evaluation of Efficacy of Microneedling and Topical Methotrexate Versus Microneedling and Topical 5-Flourouracil in Treatment of Vitiligo Patients | |
| JP2011506413A (ja) | 瘢痕化阻害の方法 | |
| CN121775001A (zh) | 一种b族维生素及其在制备治疗白癜风病药物、保健食品和膳食营养补充剂中的应用 | |
| Paller et al. | 40. Efficacy and Safety of Dupilumab in Children Aged≥ 6 Months to< 6 Years with Moderate-to-Severe Atopic Dermatitis | |
| MD1910Z (ro) | Metodă de tratament al paraliziei nervului facial | |
| WO1995023580A1 (en) | Preventive and remedy for secondary depilation | |
| WO2001056606A1 (en) | Remedies for ophthalmic diseases | |
| US20230364095A1 (en) | Topical treatment of vitiligo | |
| JP2006509773A (ja) | 持続性アレルギー性鼻炎の治療のためのレボセチリジンの使用 | |
| Jin et al. | Effect of recombinant human growth hormone add on therapy on acute stroke outcome |